Showing results (451-460 of 531) with videos related to

Sort By:
Pageof 54
The International Journal of Biochemistry & Cell Biology|November 26, 2021
HuaChanSu suppresses tumor growth and interferes with glucose metabolism in hepatocellular carcinoma cells by restraining Hexokinase-2Qi Wu, Shao-Ping Wang, Xiao-Xue Sun, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2010
In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell linesHua Cheng, She-Juan An, Xu-Chao Zhang, et al.
Physical Review Letters|June 30, 2018
Experimental Machine Learning of Quantum StatesJun Gao, Lu-Feng Qiao, Zhi-Qiang Jiao, et al.
Medical Oncology (Northwood, London, England)|October 2, 2014
Overexpression of miR-223 correlates with tumor metastasis and poor prognosis in patients with colorectal cancerZe-wu Li, Yong-mei Yang, Lu-tao Du, et al.
European Journal of Pharmacology|June 29, 2007
The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with GefitinibQiang Nie, Zhen Wang, Guo-Chun Zhang, et al.
Analytical Chemistry|March 11, 2025
Rapid Bacterial/Viral Infections Typing Strategy Using a Portable Dual-Channel Electrochemical Biosensor Based on One-Step Assembly of Immunomagnetic BeadsTai-Cheng Lu, Wen-Biao Xiao, Hui-Yun Tian, et al.
Translational Lung Cancer Research|July 11, 2026
Lobectomy, segmentectomy, and wedge resection for elderly patients with solid-predominant stage I NSCLC: survival, pulmonary function, and postoperative outcomesYaoxi Zhang, Yudong Tang, Kunhao Wu, et al.
BMC Psychiatry|December 17, 2011
Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?Marianne Ulcickas Yood, Gerald N Delorenze, Charles P Quesenberry, et al.
Plos One|May 25, 2013
A novel epitope from CD22 regulates Th1 and Th17 cell function in systemic lupus erythematosusJing Yuan, Miao Yu, Ai-Lin Cao, et al.
Cancer Letters|April 15, 2008
Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signalsJian-quan Zhu, Wen-zhao Zhong, Guo-chun Zhang, et al.
Pageof 54